| Top Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Leases Leasing > Explore An Effective Revolutionary Approach To Traditional Business Financing |
|
Top Articles - Explore An Effective Revolutionary Approach To Traditional Business Financing
For business owners who need working capital now there is a revolutionary, tax-deductible cash flow sol According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ution that frees up capital and gives them the money they need to grow. This diversified cash flow solu ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in tions is known as “asset leasing.” With an asset lease, business owners can obtain quick cash for any lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. company need by simply selling their equipment and leasing it back. Businesses not only receive immedia here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe te working capital or cash, most also realize significant tax savings from converting the assets into l d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro iabilities and by deducting the entire monthly lease payment as an operating expense. This cash flow f ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc inancing solution is available to all businesses and industries who own virtually any type of equipment easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi including industrial, medical, automotive, food service, construction, office automation, audio/video, nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically printing, packaging and much, much more. Business owners love the ease and flexibility of this financ and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ing vehicle when compared to a traditional bank loan. Bank loans that involve used equipment as collat ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ral are usually time consuming, often requiring substantial application fees, down payments etc. and co ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a llateral coverage well above the value of the financing. Most bank loans will also require the business dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod to stipulate in detail exactly how the funds will be used. With asset leasing, the equipment is the o cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin nly collateral and the money can be used for any purpose that the business owner has, for example: payi tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen ng off debt or making tax payments. There are no up-front application fees, and the entire process can t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel be completed quickly and easily by e-mail, fax and phone. To qualify: the company in most circumstance ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust s must simply have at least a two-year time in business, an acceptable credit history and own and the e y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products quipment “free and clear.” To find out more about how you can get the working capital you need now thr . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ough asset leasing, call Diversified Cash Flow Specialist Opal R. Gilbert today at 212-685-1729 or toll elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip -free at 1-888-241-3267. You may also reach her via fax at 212-686-1742 or by e-mail: lendingog@aol.com tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:How to Conquer Job Hunting Apathy
|